South Dakota Investment Council lifted its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 53.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,800 shares of the medical instruments supplier’s stock after purchasing an additional 5,500 shares during the period. South Dakota Investment Council’s holdings in AngioDynamics were worth $361,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Financial Gravity Companies Inc. purchased a new stake in AngioDynamics during the 4th quarter worth approximately $43,000. Quantamental Technologies LLC purchased a new stake in AngioDynamics during the 4th quarter worth approximately $67,000. Advisor Group Inc. increased its stake in AngioDynamics by 21.4% during the 4th quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 601 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in AngioDynamics by 28.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 1,181 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new stake in AngioDynamics during the 4th quarter worth approximately $113,000. Hedge funds and other institutional investors own 99.93% of the company’s stock.

ANGO has been the subject of several research reports. ValuEngine lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, April 19th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Wednesday, April 24th. TheStreet cut AngioDynamics from a “b” rating to a “c+” rating in a report on Thursday, April 18th. Finally, BidaskClub upgraded AngioDynamics from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $23.50.

ANGO opened at $19.52 on Thursday. AngioDynamics, Inc. has a one year low of $18.11 and a one year high of $25.48. The company has a market capitalization of $731.37 million, a P/E ratio of 26.38 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.70 and a current ratio of 2.68.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Tuesday, April 2nd. The medical instruments supplier reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.03). AngioDynamics had a net margin of 1.30% and a return on equity of 5.41%. The business had revenue of $86.34 million during the quarter, compared to analyst estimates of $88.30 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. As a group, analysts anticipate that AngioDynamics, Inc. will post 0.83 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “AngioDynamics, Inc. (ANGO) Position Boosted by South Dakota Investment Council” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/05/16/angiodynamics-inc-ango-position-boosted-by-south-dakota-investment-council.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.